Stockreport

ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase

Erytech Pharma S.A. - American Depositary Shares  (ERYP) 
US:NASDAQ Investor Relations: investors.erytech.com
PDF Set-up activities for Phase 2 clinical study ongoing and patient enrollment expected to start Q3 2018 LYON, France--(BUSINESS WIRE) [Read more]